14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IMDX vs FLGT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas FLGT carries 33.7/100 (SELL) at $24.78 (7.7x Forward P/E, -37.1% operating margin).
Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. FLGT 33.7/100 SELL), FLGT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. -1883.2% operating margin) and revenue trajectory (+7.5% vs. +115.0% YoY).
Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 60.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $708.5M market capitalization and -37.1% operating margin.
OpEx & R&D Reinvestment70.9% of Rev ($234M)
90D Engineering Disclosures0 Published
Investor FAQ IMDX vs FLGT Key Questions & Quantitative Answers
As of Nov 19, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas FLGT carries 33.7/100 (SELL) at $24.78 (7.7x Forward P/E, -37.1% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. FLGT 33.7/100 SELL), FLGT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. -1883.2% operating margin) and revenue trajectory (+7.5% vs. +115.0% YoY). Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 60.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with FLGT at +7.5% YoY revenue growth and -98.6% YoY earnings growth on $330M TTM revenue (33.8% gross margin, -37.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while FLGT shifted +1500.0%. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus 70.9% of Rev ($234M) (0 disclosures) for FLGT.
FLGT screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas FLGT trades at 7.7x Forward P/E, 7.7x Trailing P/E, 1.32x PEG, and 1.9x EV/Revenue (-0.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus FLGT (-8.7% ROE) capital efficiency.
In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, FLGT carries 49.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.13β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.